Interferon alpha - sustained release

Drug Profile

Interferon alpha - sustained release

Alternative Names: Sustained release interferon alpha

Latest Information Update: 07 Jun 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator biopartners GmbH; DURECT Corporation; Minster Pharmaceuticals
  • Developer DURECT Corporation; Minster Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 07 Jun 2005 Discontinued - Preclinical for Hepatitis C treatment in Switzerland (Injection)
  • 07 Jun 2005 Discontinued - Preclinical for Hepatitis C treatment in USA (Injection)
  • 24 Jan 2003 Preclinical trials in Hepatitis C treatment in Switzerland (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top